alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin.
Open accessThe DOI matches its Crossref record.
Abstract
The role of ornithine decarboxylase (OrnDCase, EC 4.1.1.17) and of the polyamines [putrescine (Put), spermidine (Spd), and spermine (Spm)] in mouse skin tumor promotion was investigated by the use of alpha-difluoromethylornithine (CHF2-Orn), an enzyme-activated irreversible inhibitor of OrnDCase. 12-O-Tetradecanoylphorbol 13-acetate (TPA), mezerein, and ethyl phenylpropiolate (EPP) were employed as complete, stage II specific, and nonpromoting agents, respectively. TPA and mezerein, but not EPP, provided for a dose-dependent increase in tissue Put accumulation. The Put level in papillomas developed by TPA (2 micrograms) treatment was approximately equal to 15-fold higher than that of the surrounding skin tissue; Spd accumulation was 2- to 3-fold greater in the papillomas. Put administered (intraperitoneally) with TPA greatly enhanced papilloma yield. CHF2-Orn, given orally or intraperitoneally, abolished the TPA-induced OrnDCase activity and Put accumulation in mouse epidermis. The reduction of polyamine accumulation by CHF2-Orn was directly proportional to reduction of tumor size. CHF2-Orn administered in a two-stage (TPA-mezerein) promotion protocol [Slaga, T. J., Fischer, S. M., Nelson, K. G. & Gleason, G. L. (1980) Proc. Natl. Acad. Sci. USA 77, 3659-3663; Slaga, T. J., Klein-Szanto, A. J. P., Fischer, S. M., Weeks, C. E., Nelson, K. & Major, S. (1980) Proc. Natl. Acad. Sci. USA 77, 2251-2254] reduced tumor size, inhibited by 65-70% the number of papillomas per mouse, and decreased by 40% the percentage of mice with tumors when given with the stage II agent mezerein. CHF2-Orn provided considerably less effect on tumorigenesis when administered with the TPA portion of the protocol, and CHF2-Orn did not inhibit the induction of dark basal keratinocytes by TPA. Based on our results with CHF2-Orn, we suggest that regulation of polyamine biosynthesis, particularly Put, is a critical factor in stage II promotion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prooxidant States and Tumor Promotion
Cerutti, P. A. (1985) · Science · doi:10.1126/science.2981433 · Cited by 2,497
Polyamines and cancer: old molecules, new understanding
Gerner, E. W., & Meyskens, F. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1454 · Cited by 1,159
A perspective of polyamine metabolism
WALLACE, H. M., FRASER, A. V., & HUGHES, A. (2003) · Biochemical Journal · doi:10.1042/bj20031327 · Cited by 929
Remaining mysteries of molecular biology: the role of polyamines in the cell
Miller-Fleming, L., Olin-Sandoval, V., Campbell, K., & Ralser, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.06.020 · Cited by 658
Multistage carcinogenesis in mouse skin
DiGiovanni, J. (1992) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(92)90051-z · Cited by 642
Reversible Activation of c-Myc in Skin
Pelengaris, S., Littlewood, T., Khan, M., Elia, G., & Evan, G. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80350-0 · Cited by 468
Polyamines: from Molecular Biology to Clinical Applications
Jänne, J., Alhonen, L., & Leinonen, P. (1991) · Annals of Medicine · doi:10.3109/07853899109148056 · Cited by 340
Cancer‐Protective Factors in Fruits and Vegetables: Biochemical and Biological Background.
Dragsted, L. O., Strube, M., & Larsen, J. C. (1993) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1993.tb01679.x · Cited by 333
Polyamines and cancer: implications for chemotherapy and chemoprevention
Nowotarski, S. L., Woster, P. M., & Casero, R. A. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.3 · Cited by 305
Metadata
- Authors
- Weeks, C. E., Herrmann, A. L., Nelson, F. R., & Slaga, T. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1982-10
- Volume
- 79
- Issue
- 19
- Pages
- 6028-6032
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2005740472
- Cited by
- 162
- References
- 0
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.